Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 16
Encontrada(s) 1 página(s)

Biblos-e Archivo. Repositorio Institucional de la UAM
Publicación Artículo científico (JournalArticle)

Genomic characterization of host factors related to SARS-CoV-2 infection in people with dementia and control populations: The GR@ACE/DEGESCO study

  • de Rojas, Itziar
  • Frank García, Ana
  • Montes, Angel Martín
  • Bullido Gómez-Heras, María Jesús
Artículo escrito por un elevado número de autores, solo se referencian el que aparece en primer lugar, el nombre del grupo de colaboración, si le hubiere, y los autores pertenecientes a la UAM
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Amyloid deposition in adults with drug-resistant temporal lobe epilepsy

  • Fonseca, Elena|||0000-0002-3895-1237
  • Lallana, Sofía|||0000-0002-5999-9889
  • Ortega, Gemma
  • Cano, Amanda|||0000-0001-9567-4283
  • Sarria Estrada, Silvana|||0000-0003-0083-362X
  • Pareto, Deborah|||0000-0001-7356-3769
  • Quintana, Manuel|||0000-0003-0288-9088
  • Lorenzo Bosquet, Carles|||0000-0002-8824-4602
  • López Maza, Samuel|||0000-0003-3660-2604
  • Gifreu, Ariadna
  • Campos Fernández, Daniel|||0000-0003-4795-5309
  • Abraira del Fresno, Laura|||0000-0002-5119-7929
  • Santamarina Perez, Estevo|||0000-0003-1915-0335
  • Orellana del Río, Adelina|||0000-0002-0204-1944
  • Montrreal Navarro, Laura|||0000-0002-0010-645X
  • Puerta, Raquel|||0000-0002-1191-5893
  • Aguilera, Núria
  • Ramis, Maribel
  • De Rojas, Itziar|||0000-0002-2148-381X
  • Ruiz Laza, Agustín|||0000-0003-2633-2495
  • Tárraga, Lluís|||0000-0002-8423-946X
  • Rovira, Alex|||0000-0002-2132-6750
  • Marquié, Marta|||0000-0002-0660-0950
  • Boada, Mercè|||0000-0003-2617-3009
  • Toledo, Manuel|||0000-0003-1550-3316
Objective: Pathological amyloid-β (Aβ) accumulation and hyperphosphorylated tau proteins have been described in resected temporal lobe specimens of epilepsy patients. We aimed to determine cerebrospinal fluid (CSF) Aβ1-42 and p181-tau levels and cerebral Aβ deposits on positron emission tomography (Aβ PET) and correlate these findings with cognitive performance in adults with drug-resistant temporal lobe epilepsy (TLE). Methods: In this cross-sectional study, we enrolled individuals with drug-resistant TLE who were 25-55 years old. Each participant underwent F-flutemetamol PET, determination of CSF Aβ1-42, p181-tau, and total tau, and a comprehensive neuropsychological assessment. We evaluated normalized standard uptake value ratios (SUVRs) for different brain regions on Aβ PET. Results: Thirty patients (mean age = 41.9 ± SD 8.1 years, 57% men) were included. The median disease duration was 9.5 (interquartile range = 4-24) years. Twenty-six patients (87%) had a clinically significant cognitive impairment on neuropsychological evaluation, 18 (69%) of the amnesic type. On Aβ PET, high uptake was observed in both mesial temporal regions (ipsilateral: SUVR z-score =.90, 95% confidence interval [CI] =.60-1.20; contralateral: SUVR z-score =.92, 95% CI =.57-1.27; p <.001), which was higher when compared to SUVR z-scores in all the remaining regions (p <.001) and in the ipsilateral anterior cingulate (SUVR z-score =.27, 95% CI =.04-.49, p =.020). No significant deposition was observed in other regions. Seven patients (23%) had low Aβ1-42 levels, and two (7%) had elevated p181-tau levels in CSF. Higher p181-tau levels correlated with poorer verbal fluency (R = -.427, p =.044). Significance: Our findings reveal a considerable Aβ deposition in mesial temporal regions and ipsilateral anterior cingulate among adults with drug-resistant TLE. Additionally, abnormal CSF Aβ1-42 levels were observed in a significant proportion of patients, and p181-tau levels were associated with verbal fluency. These results suggest that markers of neuronal damage can be observed in adults with TLE, warranting further investigation.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Self-reported sleep quality and longitudinal amyloid burden in clinically unimpaired adults from the AMYPAD PNHS study

  • Tort-Colet, Núria
  • Fernández-Arcos, Ana
  • Soldevila-Domenech, Natalia
  • Sánchez Benavides, Gonzalo
  • Shekari, Mahnaz
  • Vállez García, David
  • Gispert, Juan Domingo
  • Grau, Oriol (Grau Rivera)
  • AMYPAD Consortium
Background: Poor self-reported sleep quality is associated with cognitive impairment. Alzheimer's disease (AD) patients present sleep disruptions decades before they start to decline clinically. Similarly, amyloid-ß (Aß) starts accumulating during the preclinical phase of the disease. This study investigated associations between self-reported sleep quality and Aß burden longitudinally in clinically unimpaired (CU) adults. Methods: Four hundred seventeen CU adults from the AMYPAD PNHS cohort were included, with baseline self-reported sleep quality assessments (Pittsburgh Sleep Quality Index, PSQI) and longitudinal Aß PET scans. Participants were categorized by baseline Aß levels as negative (A-), grey-zone (GZ), or positive (A+). Linear mixed-effects (LME) models tested the association between baseline sleep quality and Aß burden over time, including interaction effects with baseline Aß status. Results: Global PSQI score was not associated with Aß burden over time in the entire group. However, a significant interaction with baseline Aß status was found, whereby poorer subjective sleep quality was linked to accelerated Aß accumulation in GZ participants. Conclusions: Poorer subjective sleep quality is associated with faster Aß accumulation in CU individuals with intermediate Aß levels, highlighting sleep as a potential target for early AD prevention and identifying an optimal intervention window., OG-R received support from the grant IJC2020-043417-I, funded by MCIN/AEI/https://doi.org/10.13039/501100011033 and the European Union NextGenerationEU/PRTR; this study has been funded by Instituto de Salud Carlos III (ISCIII) through the projects "PI19/00117" and "PI24/00116", co-funded by the European Union/FEDER, and through the project "CB16/10/00417" (OG-R). GS-B receives support from the grant CP23/00039 (Miguel Servet), funded by the Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union/FSE +, and receives funding from the MCIN/AEI/https://doi.org/10.13039/501100011033 through the project PID2020-119556RA-I00 and through the project PID2024-163071OB-I00, funded by MICIU/AEI/https://doi.org/10.13039/501100011033 and by the European Union FEDER. This work used data from AMYPAD PNHS that has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115952. This Joint Undertaking received support from the European Union’s Horizon 2020 research and innovation program and EFPIA. This communication reflects the views of the authors and neither IMI nor the European Union and EFPIA are liable for any use that may be made of the information contained herein. The FACEHBI study was supported with funds from Ace Alzheimer Center Barcelona, Life Molecular Imaging, Grifols, Araclon Biotech, Alkahest, Laboratorio de análisis Echevarne, and IrsiCaixa. The FACEHBI study was part of the AMYPAD-PNHS project, which received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115952. MB received funding support from CIBERNED (Instituto de Salud Carlos III (ISCIII); EU/EFPIA Innovative Medicines Initiative Joint Undertaking, ADAPTED Grant No. 115975; EXIT project, EU Euronanomed3 Program JCT2017 Grant No. AC17/00100; MOPEAD, Innovative Medicine Initiative, Grant. Nº. 115,985; PreDADQoL, ERA-NET (call 2015). Grant nº AC15/00082; TARTAGLIA (Red federada para acelerar la aplicación de la inteligencia artificial en el sistema sanitario español); PREADAPT project, Joint Program for Neurodegenerative Diseases (JPND) Grant No. AC19/00097; GECONEU Grant No. 2023–1-ELO1-KAZZ0-HED-000032173 co –founded by the European Union; Grants PI13/02434, PI16/01861, BA19/00020, and PI19/01301 from the Acción Estratégica en Salud, integrated in the Spanish National RCDCI Plan and financed by Instituto de Salud Carlos III (ISCIII)- Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER – “Una manera de Hacer Europa”); Fundació “La Caixa” and Grífols (GR@ACE project); and Proyectos de Investigación de Medicina Personalizada (ISCIII), PMP-DEGESCO, Grant Nº PMP22/00022. MM has received funding support from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement no. 796706, and the Instituto de Salud Carlos III (ISCIII) Acción Estratégica en Salud, integrated in the Spanish National RCDCI Plan and financed by ISCIII-Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER—Una manera de hacer Europa) grant PI19/00335.
Repisalud
Publicación Artículo científico (JournalArticle)

Common variants in Alzheimer's disease and risk stratification by polygenic risk scores

  • de Rojas, Itziar
  • Moreno-Grau, Sonia
  • Tesi, Niccolo
  • Grenier-Boley, Benjamin
  • Andrade, Victor
  • Jansen, Iris E
  • Pedersen, Nancy L
  • Stringa, Najada
  • Zettergren, Anna
  • Hernández, Isabel
  • Montrreal, Laura
  • Antúnez, Carmen
  • Antonell, Anna
  • Tankard, Rick M
  • Bis, Joshua C
  • Sims, Rebecca
  • Bellenguez, Céline
  • Quintela, Inés
  • González-Peréz, Antonio
  • Calero, Miguel
  • Franco-Macías, Emilio
  • Macías, Juan
  • Blesa, Rafael
  • Cervera-Carles, Laura
  • Menéndez-González, Manuel
  • Frank-García, Ana
  • Royo, José Luis
  • Moreno, Fermin
  • Huerto Vilas, Raquel
  • Baquero, Miquel
  • Diez-Fairen, Mónica
  • Lage, Carmen
  • García-Madrona, Sebastián
  • García-González, Pablo
  • Alarcón-Martín, Emilio
  • Valero, Sergi
  • Sotolongo-Grau, Oscar
  • Ullgren, Abbe
  • Naj, Adam C
  • Lemstra, Afina W
  • Benaque, Alba
  • Pérez-Cordón, Alba
  • Benussi, Alberto
  • Rábano, Alberto
  • Padovani, Alessandro
  • Squassina, Alessio
  • de Mendonça, Alexandre
  • Arias Pastor, Alfonso
  • Kok, Almar A L
  • Meggy, Alun
  • Pastor, Ana Belén
  • Espinosa, Ana
  • Corma-Gómez, Anaïs
  • Martín Montes, Angel
  • Sanabria, Ángela
  • DeStefano, Anita L
  • Schneider, Anja
  • Haapasalo, Annakaisa
  • Kinhult Ståhlbom, Anne
  • Tybjærg-Hansen, Anne
  • Hartmann, Annette M
  • Spottke, Annika
  • Corbatón-Anchuelo, Arturo
  • Rongve, Arvid
  • Borroni, Barbara
  • Arosio, Beatrice
  • Nacmias, Benedetta
  • Nordestgaard, Børge G
  • Kunkle, Brian W
  • Charbonnier, Camille
  • Abdelnour, Carla
  • Masullo, Carlo
  • Martínez Rodríguez, Carmen
  • Muñoz-Fernandez, Carmen
  • Dufouil, Carole
  • Graff, Caroline
  • Ferreira, Catarina B
  • Chillotti, Caterina
  • Reynolds, Chandra A
  • Fenoglio, Chiara
  • Van Broeckhoven, Christine
  • Clark, Christopher
  • Pisanu, Claudia
  • Satizabal, Claudia L
  • Holmes, Clive
  • Buiza-Rueda, Dolores
  • Aarsland, Dag
  • Rujescu, Dan
  • Alcolea, Daniel
  • Galimberti, Daniela
  • Wallon, David
  • Seripa, Davide
  • Grünblatt, Edna
  • Dardiotis, Efthimios
  • Düzel, Emrah
  • Scarpini, Elio
  • Conti, Elisa
  • Rubino, Elisa
  • Gelpi, Ellen
  • Rodriguez-Rodriguez, Eloy
  • Duron, Emmanuelle
  • Boerwinkle, Eric
  • Ferri, Evelyn
  • Tagliavini, Fabrizio
  • Küçükali, Fahri
  • Pasquier, Florence
  • Sanchez-Garcia, Florentino
  • Mangialasche, Francesca
  • Jessen, Frank
  • Nicolas, Gaël
  • Selbæk, Geir
  • Ortega, Gemma
  • Chêne, Geneviève
  • Hadjigeorgiou, Georgios
  • Rossi, Giacomina
  • Spalletta, Gianfranco
  • Giaccone, Giorgio
  • Grande, Giulia
  • Binetti, Giuliano
  • Papenberg, Goran
  • Hampel, Harald
  • Bailly, Henri
  • Zetterberg, Henrik
  • Soininen, Hilkka
  • Karlsson, Ida K
  • Alvarez, Ignacio
  • Appollonio, Ildebrando
  • Giegling, Ina
  • Skoog, Ingmar
  • Saltvedt, Ingvild
  • Rainero, Innocenzo
  • Rosas Allende, Irene
  • Hort, Jakub
  • Diehl-Schmid, Janine
  • Van Dongen, Jasper
  • Vidal, Jean-Sébastien
  • Lehtisalo, Jenni
  • Wiltfang, Jens
  • Thomassen, Jesper Qvist
  • Kornhuber, Johannes
  • Haines, Jonathan L
  • Vogelgsang, Jonathan
  • Pineda, Juan A
  • Fortea, Juan
  • Popp, Julius
  • Deckert, Jürgen
  • Buerger, Katharina
  • Morgan, Kevin
  • Fließbach, Klaus
  • Sleegers, Kristel
  • Molina-Porcel, Laura
  • Kilander, Lena
  • Weinhold, Leonie
  • Farrer, Lindsay A
  • Wang, Li-San
  • Kleineidam, Luca
  • Farotti, Lucia
  • Parnetti, Lucilla
  • Tremolizzo, Lucio
  • Hausner, Lucrezia
  • Benussi, Luisa
  • Froelich, Lutz
  • Ikram, M Arfan
  • Deniz-Naranjo, M Candida
  • Tsolaki, Magda
  • Rosende-Roca, Maitée
  • Löwenmark, Malin
  • Hulsman, Marc
  • Spallazzi, Marco
  • Pericak-Vance, Margaret A
  • Esiri, Margaret
  • Bernal Sánchez-Arjona, María
  • Dalmasso, Maria Carolina
  • Martínez-Larrad, María Teresa
  • Arcaro, Marina
  • Nöthen, Markus M
  • Fernández-Fuertes, Marta
  • Dichgans, Martin
  • Ingelsson, Martin
  • Herrmann, Martin J
  • Scherer, Martin
  • Vyhnalek, Martin
  • Kosmidis, Mary H
  • Yannakoulia, Mary
  • Schmid, Matthias
  • Ewers, Michael
  • Heneka, Michael T
  • Wagner, Michael
  • Scamosci, Michela
  • Kivipelto, Miia
  • Hiltunen, Mikko
  • Zulaica, Miren
  • Alegret, Montserrat
  • Fornage, Myriam
  • Roberto, Natalia
  • van Schoor, Natasja M
  • Seidu, Nazib M
  • Banaj, Nerisa
  • Armstrong, Nicola J
  • Scarmeas, Nikolaos
  • Scherbaum, Norbert
  • Goldhardt, Oliver
  • Hanon, Oliver
  • Peters, Oliver
  • Skrobot, Olivia Anna
  • Quenez, Olivier
  • Lerch, Ondrej
  • Bossù, Paola
  • Caffarra, Paolo
  • Dionigi Rossi, Paolo
  • Sakka, Paraskevi
  • Hoffmann, Per
  • Holmans, Peter A
  • Fischer, Peter
  • Riederer, Peter
  • Yang, Qiong
  • Marshall, Rachel
  • Kalaria, Rajesh N
  • Mayeux, Richard
  • Vandenberghe, Rik
  • Cecchetti, Roberta
  • Ghidoni, Roberta
  • Frikke-Schmidt, Ruth
  • Sorbi, Sandro
  • Hägg, Sara
  • Engelborghs, Sebastiaan
  • Helisalmi, Seppo
  • Botne Sando, Sigrid
  • Kern, Silke
  • Archetti, Silvana
  • Boschi, Silvia
  • Fostinelli, Silvia
  • Gil, Silvia
  • Mendoza, Silvia
  • Mead, Simon
  • Ciccone, Simona
  • Djurovic, Srdjan
  • Heilmann-Heimbach, Stefanie
  • Riedel-Heller, Steffi
  • Kuulasmaa, Teemu
  • Del Ser, Teodoro
  • Lebouvier, Thibaud
  • Polak, Thomas
  • Ngandu, Tiia
  • Grimmer, Timo
  • Bessi, Valentina
  • Escott-Price, Valentina
  • Giedraitis, Vilmantas
  • Deramecourt, Vincent
  • Maier, Wolfgang
  • Jian, Xueqiu
  • Pijnenburg, Yolande A L
  • Kehoe, Patrick Gavin
  • Garcia-Ribas, Guillermo
  • Sánchez-Juan, Pascual
  • Pastor, Pau
  • Pérez-Tur, Jordi
  • Piñol-Ripoll, Gerard
  • Lopez de Munain, Adolfo
  • García-Alberca, Jose María
  • Bullido, María Jesús
  • Álvarez, Victoria
  • Lleó, Alberto
  • Real, Luis M
  • Mir, Pablo
  • Medina, Miguel
  • Scheltens, Philip
  • Holstege, Henne
  • Marquié, Marta
  • Sáez, María Eugenia
  • Carracedo, Ángel
  • Amouyel, Philippe
  • Schellenberg, Gerard D
  • Williams, Julie
  • Seshadri, Sudha
  • van Duijn, Cornelia M
  • Mather, Karen A
  • Sánchez-Valle, Raquel
  • Serrano-Ríos, Manuel
  • Orellana, Adelina
  • Tárraga, Lluís
  • Blennow, Kaj
  • Huisman, Martijn
  • Andreassen, Ole A
  • Posthuma, Danielle
  • Clarimón, Jordi
  • Boada, Mercè
  • van der Flier, Wiesje M
  • Ramirez, Alfredo
  • Lambert, Jean-Charles
  • van der Lee, Sven J
  • Ruiz, Agustín
Genetic discoveries of Alzheimer's disease are the drivers of our understanding, and together with polygenetic risk stratification can contribute towards planning of feasible and efficient preventive and curative clinical trials. We first perform a large genetic association study by merging all available case-control datasets and by-proxy study results (discovery n = 409,435 and validation size n = 58,190). Here, we add six variants associated with Alzheimer's disease risk (near APP, CHRNE, PRKD3/NDUFAF7, PLCG2 and two exonic variants in the SHARPIN gene). Assessment of the polygenic risk score and stratifying by APOE reveal a 4 to 5.5 years difference in median age at onset of Alzheimer's disease patients in APOE ɛ4 carriers. Because of this study, the underlying mechanisms of APP can be studied to refine the amyloid cascade and the polygenic risk score provides a tool to select individuals at high risk of Alzheimer's disease.
Repisalud
Publicación Artículo científico (JournalArticle)

Genomic Characterization of Host Factors Related to SARS-CoV-2 Infection in People with Dementia and Control Populations: The GR@ACE/DEGESCO Study

  • de Rojas, Itziar
  • Hernández, Isabel
  • Montrreal, Laura
  • Quintela, Inés
  • Calero, Miguel
  • Royo, José Luis
  • Huerto Vilas, Raquel
  • González-Pérez, Antonio
  • Franco-Macías, Emilio
  • Macías, Juan
  • Menéndez-González, Manuel
  • Frank-García, Ana
  • Diez-Fairen, Mónica
  • Lage, Carmen
  • García-Madrona, Sebastián
  • Aguilera, Nuria
  • García-González, Pablo
  • Puerta, Raquel
  • Sotolongo-Grau, Oscar
  • Alonso-Lana, Silvia
  • Rábano, Alberto
  • Arias Pastor, Alfonso
  • Pastor, Ana Belén
  • Corma-Gómez, Anaïs
  • Martín Montes, Angel
  • Martínez Rodríguez, Carmen
  • Buiza-Rueda, Dolores
  • Periñán, Maria Teresa
  • Rodriguez-Rodriguez, Eloy
  • Alvarez, Ignacio
  • Rosas Allende, Irene
  • Pineda, Juan A
  • Bernal Sánchez-Arjona, María
  • Fernández-Fuertes, Marta
  • Mendoza, Silvia
  • Del Ser, Teodoro
  • GR@ACE/DEGESCO Consortium
  • Garcia-Ribas, Guillermo
  • Sánchez-Juan, Pascual
  • Pastor, Pau
  • Bullido, María Jesús
  • Álvarez, Victoria
  • Real, Luis M
  • Mir, Pablo
  • Piñol-Ripoll, Gerard
  • García-Alberca, Jose María
  • Medina, Miguel
  • Orellana, Adelina
  • Butler, Chris R
  • Marquié, Marta
  • Sáez, María Eugenia
  • Carracedo, Ángel
  • Tárraga, Lluís
  • Boada, Mercè
  • Ruiz, Agustín
Emerging studies have suggested several chromosomal regions as potential host genetic factors involved in the susceptibility to SARS-CoV-2 infection and disease outcome. We nested a COVID-19 genome-wide association study using the GR@ACE/DEGESCO study, searching for susceptibility factors associated with COVID-19 disease. To this end, we compared 221 COVID-19 confirmed cases with 17,035 individuals in whom the COVID-19 disease status was unknown. Then, we performed a meta-analysis with the publicly available data from the COVID-19 Host Genetics Initiative. Because the APOE locus has been suggested as a potential modifier of COVID-19 disease, we added sensitivity analyses stratifying by dementia status or by disease severity. We confirmed the existence of the 3p21.31 region (LZTFL1, SLC6A20) implicated in the susceptibility to SARS-CoV-2 infection and TYK2 gene might be involved in COVID-19 severity. Nevertheless, no statistically significant association was observed in the COVID-19 fatal outcome or in the stratified analyses (dementia-only and non-dementia strata) for the APOE locus not supporting its involvement in SARS-CoV-2 pathobiology or COVID-19 prognosis.
Addi. Archivo Digital para la Docencia y la Investigación
Publicación Artículo científico (JournalArticle)

Genome-wide association analysis of dementia and its clinical endophenotypes reveal novel loci associated with Alzheimer's disease and three causality networks: The GR@ACE project

  • GRACE Consortium
  • DEGESCO Consortium
  • Alzheimer’s Disease Neuroimaging Initiative
  • GRACE Study Group
  • Martínez de Pancorbo Gómez, María de los Angeles
  • López de Munain Arregui, Adolfo José
Introduction: Large variability among Alzheimer's disease (AD) cases might impact genetic discoveries and complicate dissection of underlying biological pathways. Methods: Genome Research at Fundacio ACE (GR@ACE) is a genome-wide study of dementia and its clinical endophenotypes, defined based on AD's clinical certainty and vascular burden. We assessed the impact of known AD loci across endophenotypes to generate loci categories. We incorporated gene coexpression data and conducted pathway analysis per category. Finally, to evaluate the effect of heterogeneity in genetic studies, GR@ACE series were meta-analyzed with additional genome-wide association study data sets. Results: We classified known AD loci into three categories, which might reflect the disease clinical heterogeneity. Vascular processes were only detected as a causal mechanism in probable AD. The meta-analysis strategy revealed the ANKRD31-rs4704171 and NDUFAF6-rs10098778 and confirmed SCIMP-rs7225151 and CD33-rs3865444. Discussion: The regulation of vasculature is a prominent causal component of probable AD. GR@ACE meta-analysis revealed novel AD genetic signals, strongly driven by the presence of clinical heterogeneity in the AD series. (C) 2019 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer's Association., The authors would like to thank patients and controls who participated in this project. The Genome Research @ Fundacio ACE project (GR@ACE) is supported by Fundacion bancaria "La Caixa", Grifols SA, Fundacio ACE, and ISCIII (Ministry of Health, Spain). They also want to thank the private sponsors who support the basic and clinical projects of our institution (Piramal AG, Laboratorios Echevarne, Araclon Biotech S.A., and Fundacio ACE). They are indebted to the Trinitat Port-Carbo legacy and her family for their support of Fundacio ACE research programs. Fundacio ACE is a participating center in the Dementia Genetics Spanish Consortium (DEGESCO). A.R. and M.B. receive support from the European Union/EFPIA Innovative Medicines Initiative Joint undertaking ADAPTED and MOPEAD projects (grant numbers 115975 and 115985, respectively). M.B. and A.R. are also supported by national grants PI13/02434, PI16/01861, and PI17/01474. Accion Estrategica en Salud is integrated into the Spanish National R + D + I Plan and funded by ISCIII (Instituto de Salud Carlos III)-Subdireccion General de Evaluacion and the Fondo Europeo de Desarrollo Regional (FEDER-"Una manera de Hacer Europa"). L.M.R. is supported by Consejeria de Salud de la Junta de Andalucia (grant PI-0001/2017). Control samples and data from patients included in this study were provided in part by the National DNA Bank Carlos III (www.bancoadn.org, University of Salamanca, Spain) and Hospital Universitario Virgen de Valme (Sevilla, Spain); they were processed after standard operating procedures with the appropriate approval of the Ethical and Scientific Committee. The present work was performed as part of the Biochemistry, Molecular Biology, and Biomedicine doctoral program of S. MorenoGrau at Universitat Autonoma de Barcelona (Barcelona, Spain). Data collection and sharing for this project was partially funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). The ADNI is funded by the National Institute on Aging and the National Institute of Biomedical Imaging and Bioengineering, as well as through generous contributions from the following: AbbVie; the Alzheimer's Association; the Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research provides funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study was coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for NeuroImaging at the University of Southern California. The AddNeuroMed data are from a public-private partnership supported by EFPIA companies and SMEs as part of InnoMed (Innovative Medicines in Europe), an integrated project funded by the European Union of the Sixth Framework program priority FP6-2004-LIFESCIHEALTH-5. Clinical leads responsible for data collection are Iwona K1oszewska (Lodz), Simon Lovestone (London), Patrizia Mecocci (Perugia), Hilkka Soininen (Kuopio), Magda Tsolaki (Thessaloniki), and Bruno Vellas (Toulouse). Imaging leads are Andy Simmons (London), Lars-Olad Wahlund (Stockholm), and Christian Spenger (Zurich). Bioinformatics leads are Richard Dobson (London) and Stephen Newhouse (London). Funding support for the Alzheimer's Disease Genetics Consortium (ADGC) was provided through the NIA Division of Neuroscience (U01-AG032984). The Mayo Clinic Alzheimer's Disease Genetic Studies, led by Dr. Nilufer Ertekin-Taner and Dr. Steven G. Younkin at the Mayo Clinic in Jacksonville, FL, used samples from the Mayo Clinic Study of Aging, the Mayo Clinic Alzheimer's Disease Research Center, and the Mayo Clinic Brain Bank. Data collection was supported through funding by NIA grants P50 AG016574, R01 AG032990, U01 AG046139, R01 AG018023, U01 AG006576, U01 AG006786, R01 AG025711, R01 AG017216, and R01 AG003949, NINDS grant R01 NS080820, the CurePSP Foundation, and support from the Mayo Foundation. The Neocodex-Murcia study was funded by the Fundacion Alzheimur (Murcia), the Ministerio de Educacion y Ciencia (Gobierno de Espana), Corporacion Tecnologica de Andalucia, Agencia IDEA (Consejeria de Innovacion, Junta de Andalucia), the Diabetes Research Laboratory, and the Biomedical Research Foundation. University Hospital Clinico San Carlos has been supported by CIBER de Diabetes y Enfermedades Metabolicas Asociadas (CIBERDEM); CIBERDEM is an ISCIII Project. The ROS/MAP study data were provided by the Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago. Data collection was supported through funding by NIA grants P30AG10161, R01AG15819, R01AG17917, R01AG30146, R01AG36836, U01AG32984 and U01AG46152, the Illinois Department of Public Health, and the Translational Genomics Research Institute. The TGEN study was supported by Kronos Life Science Laboratories, the National Institute on Aging (Arizona Alzheimer's Disease Center grants P30 AG19610 and RO1 AG023193, the Mayo Clinic Alzheimer's Disease Center grant P50 AG16574, and the Intramural Research Program), the National Alzheimer's Coordinating Center (U01 AG016976), and the state of Arizona. The authors thank the International Genomics of Alzheimer's Project (IGAP) for providing summary result data for these analyses. The investigators within IGAP contributed to the design and implementation of IGAP and/or provided data but did not participate in analysis or writing of this report. IGAP was made possible by the generous participation of the control subjects, the patients, and their families. The i-Select chip was funded by the French National Foundation on Alzheimer's disease and related disorders. European Alzheimer's Disease Initiative (EADI) was supported by the LABEX (laboratory of excellence program investment for the future) DISTALZ grant, Inserm, Institut Pasteur de Lille, Universite de Lille 2, and the Lille University Hospital. GERAD was supported by the Medical Research Council (grant no. 503480), Alzheimer's Research UK (grant no. 503176), the Wellcome Trust (grant no. 082604/2/07/Z), and German Federal Ministry of Education and Research (BMBF): Competence Network Dementia (CND) grant no. 01GI0102, 01GI0711, 01GI0420. CHARGE was partly supported by the NIH/NIA grant R01 AG033193 and the NIA AG081220 and AGES contract N01-AG12100, the NHLBI grant R01 HL105756, the Icelandic Heart Association, and the Erasmus Medical Center and Erasmus University. ADGC was supported by the NIH/NIA grants: U01 AG032984, U24 AG021886, U01 AG016976, and the Alzheimer's Association grant ADGC-10-196728.
Addi. Archivo Digital para la Docencia y la Investigación
Publicación Artículo científico (JournalArticle)

Common Variants in Alzheimer’s Disease and Risk Stratification by Polygenic Risk Scores

  • De Rojas, Itziar
  • EADB contributors
  • The GR@ACE study group
  • DEGESCO Consortium
  • IGAP (ADGC, CHARGE, EADI, GERAD)
  • PGC-ALZ consortia
  • López de Munain Arregui, Adolfo José
Genetic discoveries of Alzheimer's disease are the drivers of our understanding, and together with polygenetic risk stratification can contribute towards planning of feasible and efficient preventive and curative clinical trials. We first perform a large genetic association study by merging all available case-control datasets and by-proxy study results (discovery n=409,435 and validation size n=58,190). Here, we add six variants associated with Alzheimer's disease risk (near APP, CHRNE, PRKD3/NDUFAF7, PLCG2 and two exonic variants in the SHARPIN gene). Assessment of the polygenic risk score and stratifying by APOE reveal a 4 to 5.5 years difference in median age at onset of Alzheimer's disease patients in APOE ɛ4 carriers. Because of this study, the underlying mechanisms of APP can be studied to refine the amyloid cascade and the polygenic risk score provides a tool to select individuals at high risk of Alzheimer's disease., The present work has been performed as part of the doctoral program of I. de Rojas at the Universitat de Barcelona (Barcelona, Spain) supported by national grant from the Instituto de Salud Carlos III FI20/00215. The Genome Research @ Fundació ACE project (GR@ACE) is supported by Grifols SA, Fundación bancaria “La Caixa”, Fundació ACE, and CIBERNED. A.R. and M.B. receive support from the European Union/EFPIA Innovative Medicines Initiative Joint undertaking ADAPTED and MOPEAD projects (grant numbers 115975 and 115985, respectively). M.B. and A.R. are also supported by national grants PI13/02434, PI16/01861, PI17/01474, PI19/01240 and PI19/01301. Acción Estratégica en Salud is integrated into the Spanish National R + D + I Plan and funded by ISCIII (Instituto de Salud Carlos III)—Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER—“Una manera de hacer Europa”). The Alzheimer Center Amsterdam is supported by Stichting Alzheimer Nederland and Stichting VUmc fonds. The clinical database structure was developed with funding from Stichting Dioraphte. Genotyping of the Dutch case-control samples was performed in the context of EADB (European Alzheimer DNA biobank) funded by the JPco-fuND FP-829-029 (ZonMW project number 733051061). 100-Plus study. This work was supported by Stichting Alzheimer Nederland (WE09.2014-03), Stichting Diorapthe, horstingstuit foundation, Memorabel (ZonMW project number 733050814, 733050512) and Stichting VUmc Fonds. Genotyping of the 100-Plus Study was performed in the context of EADB (European Alzheimer DNA biobank) funded by the JPco-fuND FP-829-029 (ZonMW project numb 733051061). Longitudinal Aging Study Amsterdam (LASA) is largely supported by a grant from the Netherlands Ministry of Health, Welfare and Sports, Directorate of LongTerm Care. This work was supported by a grant (European Alzheimer DNA BioBank, EADB) from the EU Joint Program—Neurodegenerative Disease Research (JPND) and also funded by Inserm, Institut Pasteur de Lille, the Lille Métropole Communauté Urbaine, the French government’s LABEX DISTALZ program (development of innovative strategies for a transdisciplinary approach to AD). Genotyping of the German case-control samples was performed in the context of EADB (European Alzheimer DNA biobank) funded by the JPco-fuND (German Federal Ministry of Education and Research, BMBF: 01ED1619A). The i–Select chips was funded by the French National Foundation on AD and related disorders. EADI was supported by the LABEX (laboratory of excellence program investment for the future) DISTALZ grant, Inserm, Institut Pasteur de Lille, Université de Lille 2 and the Lille University Hospital. GERAD was supported by the Medical Research Council (Grant n° 503480), Alzheimer’s Research UK (Grant n° 503176), the Wellcome Trust (Grant n° 082604/2/07/Z) and German Federal Ministry of Education and Research (BMBF): Competence Network Dementia (CND) grant n° 01GI0102, 01GI0711, 01GI0420. CHARGE was partly supported by the NIA/NHLBI grants AG049505, AG058589, HL105756 and AGES contract N01–AG–12100, the Icelandic Heart Association, and the Erasmus Medical Center and Erasmus University. ADGC was supported by the NIH/NIA grants: U01 AG032984, U24 AG021886, U01 AG016976, and the Alzheimer’s Association grant ADGC–10–196728
Biblos-e Archivo. Repositorio Institucional de la UAM
Publicación Artículo científico (JournalArticle)

Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores

  • de Rojas, Itziar
  • Frank García, Ana
  • Bullido Gómez-Heras, María Jesús
Artículo escrito por un elevado número de autores, solo se referencian el que aparece en primer lugar, el nombre del grupo de colaboración, si le hubiere, y los autores pertenecientes a la UAM
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

Genome-wide association analysis of dementia and its clinical endophenotypes reveal novel loci associated with Alzheimer's disease and three causality networks: The GR@ACE project.

  • Moreno-Grau, Sonia
  • de Rojas, Itziar
  • Hernández Alvarez, María Isabel
  • Quintela, Inés
  • Montrreal, Laura
  • Alegret, Montserrat
  • Hernández-Olasagarre, Begoña
  • Madrid, Laura
  • González-Perez, Antonio
  • Maroñas, Olalla
  • Rosende-Roca, Maitée
  • Mauleón, Ana
  • Vargas, Liliana
  • Lafuente, Asunción
  • Abdelnour, Carla
  • Rodríguez-Gómez, Octavio
  • Gil, Silvia
  • Santos-Santos, Miguel Ángel
  • Espinosa Cardiel, Ana
  • Ortega, Gemma
  • Sanabria, Ángela
  • Pérez-Cordón, Alba
  • Cañabate, Pilar
  • Moreno, Mariola
  • Preckler, Silvia
  • Ruiz, Susana
  • Aguilera, Nuria
  • Pineda, Juan Antonio
  • Macías, Juan
  • Alarcón-Martín, Emilio
  • Sotolongo-Grau, Oscar
  • GR@ACE consortium
  • DEGESCO consortium
  • Alzheimer&apos;s Disease Neuroimaging Initiative
  • Marquié, Marta
  • Monté Rubio, Gemma C.
  • Valero, Sergi
  • Benaque, Alba
  • Clarimón, Jordi
  • Bullido, María Jesús
  • García-Ribas, Guillermo
  • Pastor, Pau
  • Sánchez-Juan, Pascual
  • Álvarez, Victoria
  • Piñol-Ripoll, Gerard
  • García-Alberca, Jose Maria
  • Royo, José Luis
  • Franco, Emilio
  • Mir, Pablo
  • Calero, Miguel
  • Medina, Miguel
  • Rábano, Alberto
  • Ávila, Jesús
  • Antúnez, Carmen
  • Real, Luis Miguel
  • Orellana, Adelina
  • Carracedo Álvarez, Ángel
  • Saéz, Maria Eugenia
  • Tárraga, Lluís
  • Boada, Mercè
  • Ruiz, Agustín
Introduction: Large variability among Alzheimer's disease (AD) cases might impact genetic discoveries and complicate dissection of underlying biological pathways. Methods: Genome Research at Fundacio ACE (GR@ACE) is a genome-wide study of dementia and its clinical endophenotypes, defined based on AD's clinical certainty and vascular burden. We assessed the impact of known AD loci across endophenotypes to generate loci categories. We incorporated gene coexpression data and conducted pathway analysis per category. Finally, to evaluate the effect of heterogeneity in genetic studies, GR@ACE series were meta-analyzed with additional genome-wide association study data sets. Results: We classified known AD loci into three categories, which might reflect the disease clinical heterogeneity. Vascular processes were only detected as a causal mechanism in probable AD. The meta-analysis strategy revealed the ANKRD31-rs4704171 and NDUFAF6-rs10098778 and confirmed SCIMP-rs7225151 and CD33-rs3865444. Discussion: The regulation of vasculature is a prominent causal component of probable AD. GR@ACE meta-analysis revealed novel AD genetic signals, strongly driven by the presence of clinical heterogeneity in the AD series.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Common variants in Alzheimer's disease and risk stratification by polygenic risk scores

  • Rojas, Itziar de
  • Moreno-Grau, Sonia
  • Tesi, Niccolo
  • Grenier-Boley, Benjamin
  • Andrade, Victor
  • Jansen, Iris E.
  • Pedersen, N. L.
  • Stringa, N.
  • Zettergren, Anna
  • Hernández, Isabel
  • Montrreal, Laura
  • Rossi, Giacomina
  • Tankard, R. M.
  • Wiltfang, J.
  • Giegling, Ina
  • Seidu, N. M.
  • Dalmasso, Maria Carolina
  • Benussi, A.
  • Boschi, Silvia
  • Sáez, María Eugenia
  • Binetti, Giuliano
  • Royo, José Luis
  • Pérez-Tur, Jordi
  • Spalletta, Gianfranco
  • Corbaton-Anchuelo, A.
  • Froelich, L.
  • Satizabal, Claudia L.
  • Hagg, S.
  • Ortega, G.
  • Peters, Oliver
  • Vogelgsang, Jonathan
  • Serrano-Ríos, M.
  • Gil, S.
  • Djurovic, Srdjan
  • Van Dongen, Jasper
  • Deramecourt, V.
  • Kalaria, R. N.
  • Wang, L. S.
  • Goldhardt, O.
  • Charbonnier, Camille
  • Farotti, Lucia
  • Kornhuber, Johannes
  • Andreassen, Ole A.
  • Álvarez, Victoria
  • Herrmann, Martin J.
  • Pasquier, Florence
  • Calero, Miguel
  • Holmes, Clive
  • Haapasalo, Annakaisa
  • Scherbaum, Norbert
  • Scheltens, Philip
  • Caffarra, P.
  • Pineda, Juan A.
  • Del Ser, Teodoro
  • Hort, Jakub
  • Espinosa, A.
  • Bullido, María Jesús
  • Hampel, Harald
  • Medina, Miguel
  • Williams, Julie
  • Sims, Rebecca
  • Martinez-Larrad, M. T.
  • Riederer, Peter
  • Esiri, M.
  • Botne Sando, S.
  • Grunblatt, E.
  • Hoffmann, Per
  • Hiltunen, Mikko
  • Kern, Silke
  • Mendoza, Silvia
  • Kilander, Lena
  • Jessen, F.
  • Ghidoni, R.
  • Giedraitis, Vilmantas
  • Molina-Porcel, Laura
  • Sánchez-Juan, Pascual
  • Schmid, Matthias
  • van Duijn, Cornelia M.
  • Antonell, A.
  • Mir, Pablo
  • Moreno, F.
  • Ferreira, Catarina B.
  • Skrobot, Olivia
  • Sánchez-Valle, Raquel
  • Chene, G.
  • Duron, Emmanuelle
  • Martín Montes, Ángel
  • Ciccone, Simona
  • Piñol-Ripoll, Gerard
  • Ngandu, Tiia
  • Dardiotis, Efthimios
  • Scherer, Martin
  • Arosio, Beatrice
  • Meggy, A.
  • Sotolongo-Grau, Oscar
  • Selbaek, Geir
  • Aarsland, Dag
  • Seshadri, Sudha
  • Bailly, Henri
  • Sánchez-García, Florentino
  • Roberto, Natalia
  • Armstrong, Nicola J.
  • Farrer, Lindsay A.
  • Popp, Julius
  • Riedel-Heller, Steffi
  • Fernández-Fuertes, Marta
  • Scamosci, Michela
  • Alcolea, Daniel
  • Rosas Allende, Irene
  • Marquié, Marta
  • Benussi, Luisa
  • Ewers, Michael
  • Antúnez, Carmen
  • van Broeckhoven, Christine
  • Masullo, C.
  • Vyhnalek, Martin
  • Bossu, Paola
  • Appollonio, I.
  • Mayeux, R.
  • Lerch, Ondrej
  • Rábano, Alberto
  • Quenez, Olivier
  • Schneider, Anja
  • Wallon, David
  • Macías Sánchez, Juan
  • PGC-ALZ consortia
  • Yang, Q.
  • Helisalmi, Seppo
  • Huisman, M.
  • Lambert, Jean-Charles
  • Kehoe, Patrick G.
  • Heneka, Michael T.
  • DEGESCO consortium
  • Papenberg, Goran
  • Lowenmark, M.
  • Frikke-Schmidt, Ruth
  • Fornage, Myriam
  • Kunkle, Brian W.
  • Heilmann-Heimbach, Stefanie
  • Posthuma, Danielle
  • Tremolizzo, Lucio
  • Amouyel, Philippe
  • Franco-Macías, Emilio
  • Munoz-Fernandez, C.
  • Sorbi, Sandro
  • Küçükali, Fahri
  • Dionigi Rossi, P.
  • Huerto Vilas, Raquel
  • Spallazzi, Marco
  • Alarcón-Martín, Emilio
  • Maier, Wolfgang
  • de Mendonça, Alexandre
  • The GR@ACE study group
  • Benaque, Alba
  • EADB contributors
  • IGAP (ADGC, CHARGE, EADI, GERAD)
  • van der Lee, Sven J.
  • DeStefano, Anita
  • Lleó, Alberto
  • Kosmidis, Mary H.
  • Rongve, A.
  • Nicolas, Gael
  • Escott-Price, Valentina
  • Tybjaerg-Hansen, Anne
  • Chillotti, Caterina
  • Pastor, Pau
  • Buiza-Rueda, Dolores
  • Alegret, Montserrat
  • Lage, Carmen
  • Holmans, Peter A.
  • Polak, Thomas
  • Pastor, Ana Belén
  • Nöthen, Markus M.
  • García-Ribas, Guillermo
  • Pijnenburg, Yolande A L
  • Vidal, Jean-Sebastien
  • Squassina, Alessio
  • Kuulasmaa, Teemu
  • Pericak-Vance, M. A.
  • Pisanu, Claudia
  • Fliessbach, Klaus
  • Grimmer, Timo
  • Galimberti, Daniela
  • Parnetti, L.
  • López de Munain, Adolfo
  • Soininen, Hilkka
  • Carracedo, Ángel
  • Deckert, Jurgen
  • Karlsson, I. K.
  • Buerger, Katharina
  • Clark, Christopher
  • Cecchetti, Roberta
  • Fostinelli, Silvia
  • Deniz-Naranjo, M. C.
  • Engelborghs, S.
  • Álvarez, Ignacio
  • Sakka, Paraskevi
  • Thomassen, Jesper Qvist
  • Ramirez, A.
  • Holstege, Henne
  • Marshall, Rachel
  • Haines, Jonathan L.
  • Hulsman, Marc
  • Kleineidam, Luca
  • Ferri, E.
  • Pérez-Cordón, Alba
  • Menéndez-González, Manuel
  • van der Flier, Wiesje M.
  • Rainero, Innocenzo
  • Rujescu, D.
  • Wagner, Michael
  • Corma-Gómez, Anaïs
  • Lebouvier, T.
  • Ruiz, Agustín
  • Vandenberghe, Rik
  • Weinhold, Leonie
  • Padovani, Alessandro
  • Diehl-Schmid, Janine
  • Mead, Simon
  • Fenoglio, Chiara
  • Conti, Elisa
  • Díez-Fairen, Mónica
  • Fischer, Peter
  • Abdelnour, Carla
  • Giaccone, G.
  • González-Pérez, Antonio
  • Hartmann, Annette M.
  • Hadjigeorgiou, Georgios
  • Zulaica, M.
  • Sleegers, Kristel
  • Martínez Rodríguez, Carmen
  • García-González, Pablo
  • Rubino, Elisa
  • Bis, Joshua C.
  • Orellana, Adelina
  • Zetterberg, Henrik
  • Schellenberg, Gerard D.
  • Borroni, Barbara
  • Sanabria, Angela
  • Fortea, J.
  • Reynolds, C. A.
  • Gelpí, Ellen
  • Bernal Sánchez-Arjona, María
  • Boerwinkle, Eric
  • Mather, K. A.
  • Jian, X.
  • Saltvedt, Ingvild
  • Frank-García, Ana
  • Rosende-Roca, Maitee
  • Kinhult Stahlbom, Anne
  • Hanon, Olivier
  • Skoog, Ingmar
  • Kivipelto, Miia
  • Lehtisalo, Jenni
  • García-Alberca, José María
  • Dufouil, Carole
  • Bellenguez, Celine
  • Ingelsson, Martin
  • Nacmias, B.
  • Spottke, Annika
  • Ullgren, Abbe
  • Hausner, Lucrezia
  • Arias Pastor, Alfonso
  • Tsolaki, Magda
  • Seripa, Davide
  • Naj, A. C.
  • Clarimón, Jordi
  • Nordestgaard, Borge G.
  • Valero, Sergi
  • van Schoor, N. M.
  • Scarpini, E.
  • Graff, Caroline
  • Boada, Mercè
  • Tagliavini, Fabrizio
  • Scarmeas, N.
  • García-Madrona, Sebastián
  • Yannakoulia, Mary
  • Banaj, Nerisa
  • Blennow, Kaj
  • Duzel, Emrah
  • Tárraga, Lluís
  • Lemstra, A. W.
  • Morgan, K.
  • Kok, A. A. L.
  • Bessi, Valentina
  • Baquero, Miquel
  • Rodríguez-Rodríguez, Eloy
  • Cervera-Carles, Laura
  • Archetti, Silvana
  • Grande, Giulia
  • Dichgans, Martin
  • Arcaro, Marina
  • Blesa, Rafael
  • Real, Luis Miguel
  • Ikram, M. Arfan
  • Mangialasche, Francesca
  • Quintela, Inés
16 páginas, 5 figuras, Genetic discoveries of Alzheimer's disease are the drivers of our understanding, and together with polygenetic risk stratification can contribute towards planning of feasible and efficient preventive and curative clinical trials. We first perform a large genetic association study by merging all available case-control datasets and by-proxy study results (discovery n = 409,435 and validation size n = 58,190). Here, we add six variants associated with Alzheimer's disease risk (near APP, CHRNE, PRKD3/NDUFAF7, PLCG2 and two exonic variants in the SHARPIN gene). Assessment of the polygenic risk score and stratifying by APOE reveal a 4 to 5.5 years difference in median age at onset of Alzheimer's disease patients in APOE ɛ4 carriers. Because of this study, the underlying mechanisms of APP can be studied to refine the amyloid cascade and the polygenic risk score provides a tool to select individuals at high risk of Alzheimer's disease., The present work has been performed as part of the doctoral program of I. de Rojas at the Universitat de Barcelona (Barcelona, Spain) supported by national grant from the Instituto de Salud Carlos III FI20/00215. The Genome Research @ Fundació ACE project (GR@ACE) is supported by Grifols SA, Fundación bancaria “La Caixa”, Fundació ACE, and CIBERNED. A.R. and M.B. receive support from the European Union/EFPIA Innovative Medicines Initiative Joint undertaking ADAPTED and MOPEAD projects (grant numbers 115975 and 115985, respectively). M.B. and A.R. are also supported by national grants PI13/02434, PI16/01861, PI17/01474, PI19/01240 and PI19/01301. Acción Estratégica en Salud is integrated into the Spanish National R + D + I Plan and funded by ISCIII (Instituto de Salud Carlos III)—Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER—“Una manera de hacer Europa”). Some control samples and data from patients included in this study were provided in part by the National DNA Bank Carlos III (www.bancoadn.org, University of Salamanca, Spain) and Hospital Universitario Virgen de Valme (Sevilla, Spain); they were processed following standard operating procedures with the appropriate approval of the Ethical and Scientific Committee. Amsterdam dementia Cohort (ADC): Research of the Alzheimer center Amsterdam is part of the neurodegeneration research program of Amsterdam Neuroscience. The Alzheimer Center Amsterdam is supported by Stichting Alzheimer Nederland and Stichting VUmc fonds. The clinical database structure was developed with funding from Stichting Dioraphte. Genotyping of the Dutch case-control samples was performed in the context of EADB (European Alzheimer DNA biobank) funded by the JPco-fuND FP-829-029 (ZonMW project number 733051061). 100-Plus study: We are grateful for the collaborative efforts of all participating centenarians and their family members and/or relations. This work was supported by Stichting Alzheimer Nederland (WE09.2014-03), Stichting Diorapthe, horstingstuit foundation, Memorabel (ZonMW project number 733050814, 733050512) and Stichting VUmc Fonds. Genotyping of the 100-Plus Study was performed in the context of EADB (European Alzheimer DNA biobank) funded by the JPco-fuND FP-829-029 (ZonMW project number 733051061). Longitudinal Aging Study Amsterdam (LASA) is largely supported by a grant from the Netherlands Ministry of Health, Welfare and Sports, Directorate of Long-Term Care. The authors are grateful to all LASA participants, the fieldwork team and all researchers for their ongoing commitment to the study. This work was supported by a grant (European Alzheimer DNA BioBank, EADB) from the EU Joint Program—Neurodegenerative Disease Research (JPND) and also funded by Inserm, Institut Pasteur de Lille, the Lille Métropole Communauté Urbaine, the French government’s LABEX DISTALZ program (development of innovative strategies for a transdisciplinary approach to AD). Genotyping of the German case-control samples was performed in the context of EADB (European Alzheimer DNA biobank) funded by the JPco-fuND (German Federal Ministry of Education and Research, BMBF: 01ED1619A). Full acknowledgments for the studies that contributed data can be found in the Supplementary Note. We thank the numerous participants, researchers, and staff from many studies who collected and contributed to the data. We thank the International Genomics of Alzheimer’s Project (IGAP) for providing summary results data for these analyses. The investigators within IGAP contributed to the design and implementation of IGAP and/or provided data but did not participate in analysis or writing of this report. IGAP was made possible by the generous participation of the control subjects, the patients, and their families. The i–Select chips was funded by the French National Foundation on AD and related disorders. EADI was supported by the LABEX (laboratory of excellence program investment for the future) DISTALZ grant, Inserm, Institut Pasteur de Lille, Université de Lille 2 and the Lille University Hospital. GERAD was supported by the Medical Research Council (Grant n° 503480), Alzheimer’s Research UK (Grant n° 503176), the Wellcome Trust (Grant n° 082604/2/07/Z) and German Federal Ministry of Education and Research (BMBF): Competence Network Dementia (CND) grant n° 01GI0102, 01GI0711, 01GI0420. CHARGE was partly supported by the NIA/NHLBI grants AG049505, AG058589, HL105756 and AGES contract N01–AG–12100, the Icelandic Heart Association, and the Erasmus Medical Center and Erasmus University. ADGC was supported by the NIH/NIA grants: U01 AG032984, U24 AG021886, U01 AG016976, and the Alzheimer’s Association grant ADGC–10–196728. This research has been conducted using the UK Biobank public resource obtained through the University of Edinburg Data Share (https://datashare.is.ed.ac.uk/handle/10283/3364)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Intermediate and Expanded HTT Alleles and the Risk for α-Synucleinopathies

  • Pérez-Oliveira, Sergio
  • Álvarez, Ignacio
  • Rosas Allende, Irene
  • Menéndez-González, Manuel
  • Blázquez-Estrada, Marta
  • Aguilar Barberá, Miquel
  • Corte, Daniela
  • Buongiorno, Maria Teresa
  • Molina-Porcel, Laura
  • Aldecoa, Iban
  • Martí, María-José
  • Sánchez-Juan, Pascual
  • Infante, Jon
  • González-Aramburu, Isabel
  • García-González, Pablo
  • Rosende-Roca, Maitee
  • Boada, Mercè
  • Ruiz, Agustín
  • Periñán, María Teresa
  • Macías García, Daniel
  • Muñoz-Delgado, Laura
  • Gómez-Garre, Pilar
  • Mir, Pablo
  • Clarimón, Jordi
  • Lleó, Alberto
  • Alcolea, Daniel
  • Casa-Fages, Beatriz de la
  • Duarte, Israel
  • Álvarez, Victoria
  • Pastor, Pau
[Background] Previous studies suggest a link between CAG repeat number in the HTT gene and non-Huntington neurodegenerative diseases., [Objective] The aim is to analyze whether expanded HTT CAG alleles and/or their size are associated with the risk for developing α-synucleinopathies or their behavior as modulators of the phenotype., [Methods] We genotyped the HTT gene CAG repeat number and APOE-Ɛ isoforms in a case-control series including patients with either clinical or neuropathological diagnosis of α-synucleinopathy., [Results] We identified three Parkinson's disease (PD) patients (0.30%) and two healthy controls (0.19%) carrying low-penetrance HTT repeat expansions whereas none of the dementia with Lewy bodies (DLB) or multisystem atrophy (MSA) patients carried pathogenic HTT expansions. In addition, a clear increase in the number of HTT CAG repeats was found among DLB and PD groups influenced by the male gender and also by the APOE4 allele among DLB patients. HTT intermediate alleles' (IAs) distribution frequency increased in the MSA group compared with controls (8.8% vs. 3.9%, respectively). These differences were indeed statistically significant in the MSA group with neuropathological confirmation. Two MSA HTT CAG IAs carriers with 32 HTT CAG repeats showed isolated polyQ inclusions in pons and basal nuclei, which are two critical structures in the neurodegeneration of MSA., [Conclusions] Our results point to a link between HTT CAG number, HTT IAs, and expanded HTT CAG repeats with other non-HD brain pathology and support the hypothesis that they can share common neurodegenerative pathways., This work is supported by the Fondo de Investigaciones Sanitarias' Spanish government ICIII FIS-FEDER grants (ID grants: PI21/0467 to V.A., and PI21/00886 to P.P.). Sergio Pérez-Oliveira is supported by Fundación Parkinson Asturias-Obra Social Cajastur. M.T.P. was supported by the Spanish Ministry of Education, Culture and Sports [FPU16/05061]. D.M.-G. was supported by the “Río Hortega” program [CM18/00142] from the Instituto de Salud Carlos III (ISCIII-FEDER). P.G.-G. was supported by the “Nicolás Monardes” program [C-0048-2017] from the Andalusian Regional Ministry of Health. The Genome Research @ Fundació ACE project (GR@ACE) is supported by Grifols SA, Fundación bancaria “La Caixa,” Fundació ACE, and CIBERNED. P.G. is supported by CIBERNED employment plan CNV-304-PRF-866. A.R. and M.B. receive support from the European Union/EFPIA Innovative Medicines Initiative Joint undertaking ADAPTED and MOPEAD projects (grant numbers 115975 and 115985, respectively). M.B. and A.R. are also supported by National Grants (PI13/02434, PI16/01861, PI17/01474, PI19/01240, and PI19/01301). Acción Estratégica en Salud is integrated into the Spanish National R + D + I Plan and funded by ISCIII (Instituto de Salud Carlos III)—Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER—“Una manera de hacer Europa”)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Genome-wide association analysis of dementia and its clinical endophenotypes reveal novel loci associated with Alzheimer's disease and three causality networks: The GR@ACE project.

  • Moreno-Grau, Sonia
  • de Rojas, Itziar
  • Hernández Alvarez, María Isabel
  • Quintela, Inés
  • Montrreal, Laura
  • Alegret, Montserrat
  • Hernández-Olasagarre, Begoña
  • Madrid, Laura
  • González-Perez, Antonio
  • Maroñas, Olalla
  • Rosende-Roca, Maitée
  • Mauleón, Ana
  • Vargas, Liliana
  • Lafuente, Asunción
  • Abdelnour, Carla
  • Rodríguez-Gómez, Octavio
  • Gil, Silvia
  • Santos-Santos, Miguel Ángel
  • Espinosa Cardiel, Ana
  • Ortega, Gemma
  • Sanabria, Ángela
  • Pérez-Cordón, Alba
  • Cañabate, Pilar
  • Moreno, Mariola
  • Preckler, Silvia
  • Ruiz, Susana
  • Aguilera, Nuria
  • Pineda, Juan Antonio
  • Macías, Juan
  • Alarcón-Martín, Emilio
  • Sotolongo-Grau, Oscar
  • GR@ACE consortium
  • DEGESCO consortium
  • Alzheimer's Disease Neuroimaging Initiative
  • Marquié, Marta
  • Monté Rubio, Gemma C.
  • Valero, Sergi
  • Benaque, Alba
  • Clarimón, Jordi
  • Bullido, María Jesús
  • García-Ribas, Guillermo
  • Pastor, Pau
  • Sánchez-Juan, Pascual
  • Álvarez, Victoria
  • Piñol-Ripoll, Gerard
  • García-Alberca, Jose Maria
  • Royo, José Luis
  • Franco, Emilio
  • Mir, Pablo
  • Calero, Miguel
  • Medina, Miguel
  • Rábano, Alberto
  • Ávila, Jesús
  • Antúnez, Carmen
  • Real, Luis Miguel
  • Orellana, Adelina
  • Carracedo Álvarez, Ángel
  • Saéz, Maria Eugenia
  • Tárraga, Lluís
  • Boada, Mercè
  • Ruiz, Agustín
Introduction: Large variability among Alzheimer's disease (AD) cases might impact genetic discoveries and complicate dissection of underlying biological pathways. Methods: Genome Research at Fundacio ACE (GR@ACE) is a genome-wide study of dementia and its clinical endophenotypes, defined based on AD's clinical certainty and vascular burden. We assessed the impact of known AD loci across endophenotypes to generate loci categories. We incorporated gene coexpression data and conducted pathway analysis per category. Finally, to evaluate the effect of heterogeneity in genetic studies, GR@ACE series were meta-analyzed with additional genome-wide association study data sets. Results: We classified known AD loci into three categories, which might reflect the disease clinical heterogeneity. Vascular processes were only detected as a causal mechanism in probable AD. The meta-analysis strategy revealed the ANKRD31-rs4704171 and NDUFAF6-rs10098778 and confirmed SCIMP-rs7225151 and CD33-rs3865444. Discussion: The regulation of vasculature is a prominent causal component of probable AD. GR@ACE meta-analysis revealed novel AD genetic signals, strongly driven by the presence of clinical heterogeneity in the AD series.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Self-reported sleep quality and longitudinal amyloid burden in clinically unimpaired adults from the AMYPAD PNHS study

  • Tort-Colet, Núria
  • Fernández-Arcos, Ana
  • Soldevila-Domenech, Natalia
  • Sánchez Benavides, Gonzalo
  • Shekari, Mahnaz
  • Vállez García, David
  • Gispert, Juan Domingo
  • Grau, Oriol (Grau Rivera)
  • AMYPAD Consortium
Background: Poor self-reported sleep quality is associated with cognitive impairment. Alzheimer's disease (AD) patients present sleep disruptions decades before they start to decline clinically. Similarly, amyloid-ß (Aß) starts accumulating during the preclinical phase of the disease. This study investigated associations between self-reported sleep quality and Aß burden longitudinally in clinically unimpaired (CU) adults. Methods: Four hundred seventeen CU adults from the AMYPAD PNHS cohort were included, with baseline self-reported sleep quality assessments (Pittsburgh Sleep Quality Index, PSQI) and longitudinal Aß PET scans. Participants were categorized by baseline Aß levels as negative (A-), grey-zone (GZ), or positive (A+). Linear mixed-effects (LME) models tested the association between baseline sleep quality and Aß burden over time, including interaction effects with baseline Aß status. Results: Global PSQI score was not associated with Aß burden over time in the entire group. However, a significant interaction with baseline Aß status was found, whereby poorer subjective sleep quality was linked to accelerated Aß accumulation in GZ participants. Conclusions: Poorer subjective sleep quality is associated with faster Aß accumulation in CU individuals with intermediate Aß levels, highlighting sleep as a potential target for early AD prevention and identifying an optimal intervention window., OG-R received support from the grant IJC2020-043417-I, funded by MCIN/AEI/https://doi.org/10.13039/501100011033 and the European Union NextGenerationEU/PRTR; this study has been funded by Instituto de Salud Carlos III (ISCIII) through the projects "PI19/00117" and "PI24/00116", co-funded by the European Union/FEDER, and through the project "CB16/10/00417" (OG-R). GS-B receives support from the grant CP23/00039 (Miguel Servet), funded by the Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union/FSE +, and receives funding from the MCIN/AEI/https://doi.org/10.13039/501100011033 through the project PID2020-119556RA-I00 and through the project PID2024-163071OB-I00, funded by MICIU/AEI/https://doi.org/10.13039/501100011033 and by the European Union FEDER. This work used data from AMYPAD PNHS that has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115952. This Joint Undertaking received support from the European Union’s Horizon 2020 research and innovation program and EFPIA. This communication reflects the views of the authors and neither IMI nor the European Union and EFPIA are liable for any use that may be made of the information contained herein. The FACEHBI study was supported with funds from Ace Alzheimer Center Barcelona, Life Molecular Imaging, Grifols, Araclon Biotech, Alkahest, Laboratorio de análisis Echevarne, and IrsiCaixa. The FACEHBI study was part of the AMYPAD-PNHS project, which received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115952. MB received funding support from CIBERNED (Instituto de Salud Carlos III (ISCIII); EU/EFPIA Innovative Medicines Initiative Joint Undertaking, ADAPTED Grant No. 115975; EXIT project, EU Euronanomed3 Program JCT2017 Grant No. AC17/00100; MOPEAD, Innovative Medicine Initiative, Grant. Nº. 115,985; PreDADQoL, ERA-NET (call 2015). Grant nº AC15/00082; TARTAGLIA (Red federada para acelerar la aplicación de la inteligencia artificial en el sistema sanitario español); PREADAPT project, Joint Program for Neurodegenerative Diseases (JPND) Grant No. AC19/00097; GECONEU Grant No. 2023–1-ELO1-KAZZ0-HED-000032173 co –founded by the European Union; Grants PI13/02434, PI16/01861, BA19/00020, and PI19/01301 from the Acción Estratégica en Salud, integrated in the Spanish National RCDCI Plan and financed by Instituto de Salud Carlos III (ISCIII)- Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER – “Una manera de Hacer Europa”); Fundació “La Caixa” and Grífols (GR@ACE project); and Proyectos de Investigación de Medicina Personalizada (ISCIII), PMP-DEGESCO, Grant Nº PMP22/00022. MM has received funding support from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement no. 796706, and the Instituto de Salud Carlos III (ISCIII) Acción Estratégica en Salud, integrated in the Spanish National RCDCI Plan and financed by ISCIII-Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER—Una manera de hacer Europa) grant PI19/00335.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Genome-wide meta-analysis for Alzheimer's disease cerebrospinal fluid biomarkers

  • Jansen, Iris E.|||0000-0003-1901-8131
  • van der Lee, Sven J.|||0000-0003-1606-8643
  • Gomez-Fonseca, Duber
  • De Rojas, Itziar|||0000-0002-2148-381X
  • Dalmasso, Maria Carolina|||0000-0002-4901-9955
  • Grenier-Boley, Benjamin
  • Zettergren, Anna|||0000-0002-7182-8417
  • Mishra, Aniket|||0000-0002-8141-1543
  • Ali, Muhammad|||0000-0002-1399-6631
  • Andrade, Victor|||0000-0003-0682-269X
  • Bellenguez, Céline|||0000-0002-1240-7874
  • Kleineidam, Luca
  • Küçükali, Fahri
  • Sung, Ju Sung
  • Tesí, Niccolo
  • Vromen, Ellen|||0000-0001-7774-5500
  • Wightman, Douglas P.
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Alegret, Montserrat|||0000-0002-8164-9500
  • Alvarez, Ignacio|||0000-0002-8537-3935
  • Amouyel, Philippe|||0000-0001-9088-234X
  • Athanasiu, Lavinia
  • Bahrami, Shahram
  • Bailly, Henri
  • Belbin, Olivia|||0000-0002-6109-6371
  • Bergh, Sverre|||0000-0001-9593-2967
  • Bertram, Lars|||0000-0002-0108-124X
  • Biessels, Geert Jan|||0000-0001-6862-2496
  • Blennow, Kaj|||0000-0002-1890-4193
  • Blesa, Rafael|||0000-0003-4026-2884
  • Boada, Mercè|||0000-0003-2617-3009
  • Boland, Anne|||0000-0001-8789-5676
  • Buerger, K.
  • Carracedo, Ángel|||0000-0003-1085-8986
  • Cervera Carles, Laura|||0000-0003-2286-200X
  • Chene, Geneviève|||0000-0002-8368-6460
  • Claassen, Jurgen|||0000-0002-1778-8151
  • Debette, Stéphanie|||0000-0001-8675-7968
  • Deleuze, Jean-Francois
  • De Deyn, Peter Paul|||0000-0002-2228-2964
  • Diehl-Schmid, Janine|||0000-0002-7745-1382
  • Djurovic, Srdjan|||0000-0002-8140-8061
  • Dols Icardo, Oriol|||0000-0003-2656-8748
  • Dufouil, Carole|||0000-0003-2442-4476
  • Duron, Emmanuelle
  • Düzel, Emrah
  • Fladby, Tormod|||0000-0002-9984-9797
  • Fortea, Juan|||0000-0002-1340-638X
  • Froelich, Lutz|||0000-0003-1494-0813
  • García-González, Pablo|||0000-0003-0125-5403
  • Garcia-Martinez, María
  • Giegling, Ina
  • Goldhardt, Oliver
  • Gobom, Johan|||0000-0001-6193-6193
  • Grimmer, Timo
  • Haapasalo, Annakaisa|||0000-0003-0959-2957
  • Hampel, Harald
  • Hanon, Olivier|||0000-0002-4697-122X
  • Hausner, Lucrezia|||0000-0001-9009-2356
  • Heilmann-Heimbach, Stefanie|||0000-0003-1057-465X
  • Helisalmi, Seppo
  • Heneka, Michael|||0000-0003-4996-1630
  • Hernández, Isabel|||0000-0001-8119-393X
  • Herukka, Sanna-Kaisa|||0000-0003-3308-8662
  • Holstege, Henne|||0000-0002-7688-3087
  • Jarholm, Jonas
  • Kern, Silke
  • Knapskog, Anne-Brita
  • Koivisto, A.M.
  • Kornhuber, Johannes|||0000-0002-8096-3987
  • Kuulasmaa, Teemu|||0000-0002-1795-7314
  • Lage, Carmen|||0000-0003-1703-121X
  • Laske, Christoph
  • Leinonen, Ville|||0000-0002-4282-4687
  • Lewczuk, Piotr|||0000-0002-8101-6535
  • Lleó, Alberto|||0000-0002-2568-5478
  • Lopez de Munain, Adolfo|||0000-0002-9509-4032
  • López-Garcia, Sara
  • Maier, Wolfgang
  • Marquié, Marta|||0000-0002-0660-0950
  • Mol, Merel O.|||0000-0003-2533-2530
  • Montrreal Navarro, Laura|||0000-0002-0010-645X
  • Moreno, Fermin|||0000-0001-5200-3164
  • Moreno-Grau, Sonia
  • Nicolas, Gael|||0000-0001-9391-7800
  • Nöthen, Markus M.|||0000-0002-8770-2464
  • Orellana del Río, Adelina|||0000-0002-0204-1944
  • Pålhaugen, Lene
  • Papma, Janne M.
  • Pasquier, Florence|||0000-0001-9880-9788
  • Perneczky, Robert|||0000-0003-1981-7435
  • Peters, Oliver|||0000-0003-0568-2998
  • Pijnenburg, Yolande A.L.
  • Popp, Julius|||0000-0002-0068-0312
  • Posthuma, Danielle|||0000-0001-7582-2365
  • Pozueta, Ana
  • Priller, Josef|||0000-0001-7596-0979
  • Puerta, Raquel|||0000-0002-1191-5893
  • Quintela, Inés|||0000-0002-0239-7975
  • Ramakers, Inez
  • Rodríguez-Rodríguez, Eloy|||0000-0001-7742-677X
  • Rujescu, Dan|||0000-0002-1432-313X
  • Saltvedt, Ingvild|||0000-0002-7897-9808
  • Sánchez-Juan, Pascual|||0000-0002-6081-8037
  • Scheltens, Philip|||0000-0002-1046-6408
  • Scherbaum, Norbert|||0000-0003-1759-6990
  • Schmid, Matthias
  • Schneider, Anja|||0000-0001-9540-8700
  • Selbæk, Geir|||0000-0001-6511-8219
  • Selnes, Per
  • Shadrin, Alexey
  • Skoog, Ingmar
  • Soininen, Hilkka|||0000-0002-2785-9937
  • Tárraga, Lluís|||0000-0002-8423-946X
  • Teipel, Stefan
  • Tijms, Betty M.|||0000-0002-2612-1797
  • Tsolaki, Magda|||0000-0002-2072-8010
  • Van Broeckhoven, Christine|||0000-0003-0183-7665
  • Van Dongen, Jasper|||0000-0001-5599-0046
  • van Swieten, John C.
  • Vandenberghe, Rik|||0000-0001-6237-2502
  • Vidal, Jean-Sébastien|||0000-0001-6770-0720
  • Visser, Pieter Jelle|||0000-0001-8008-9727
  • Vogelgsang, Jonathan|||0000-0001-9326-8193
  • Waern, Margda|||0000-0002-8330-6915
  • Wagner, Michael
  • Wiltfang, Jens W.
  • Wittens, Mandy M.J.
  • Zetterberg, Henrik|||0000-0003-3930-4354
  • Zulaica, Miren
  • van Duijn, Cornelia M.|||0000-0002-2374-9204
  • Bjerke, Maria
  • Engelborghs, Sebastiaan|||0000-0003-0304-9785
  • Jessen, Frank
  • Teunissen, Charlotte E.|||0000-0002-4061-0837
  • Pastor, Pau|||0000-0002-7493-8777
  • Hiltunen, Mikko|||0000-0003-3566-4096
  • Ingelsson, Martin|||0000-0001-5466-8370
  • Andreassen, Ole A.|||0000-0002-4461-3568
  • Clarimón, Jordi|||0000-0002-6824-6942
  • Sleegers, Kristel|||0000-0002-0283-2332
  • Ruiz Laza, Agustín|||0000-0003-2633-2495
  • Ramirez, Alfredo|||0000-0003-4991-763X
  • Cruchaga, Carlos|||0000-0002-0276-2899
  • Lambert, Jean-Charles|||0000-0003-0829-7817
  • van der Flier, Wiesje M.|||0000-0001-8766-6224
Amyloid-beta 42 (Aβ42) and phosphorylated tau (pTau) levels in cerebrospinal fluid (CSF) reflect core features of the pathogenesis of Alzheimer's disease (AD) more directly than clinical diagnosis. Initiated by the European Alzheimer & Dementia Biobank (EADB), the largest collaborative effort on genetics underlying CSF biomarkers was established, including 31 cohorts with a total of 13,116 individuals (discovery n = 8074; replication n = 5042 individuals). Besides the APOE locus, novel associations with two other well-established AD risk loci were observed; CR1 was shown a locus for Aβ42 and BIN1 for pTau. GMNC and C16orf95 were further identified as loci for pTau, of which the latter is novel. Clustering methods exploring the influence of all known AD risk loci on the CSF protein levels, revealed 4 biological categories suggesting multiple Aβ42 and pTau related biological pathways involved in the etiology of AD. In functional follow-up analyses, GMNC and C16orf95 both associated with lateral ventricular volume, implying an overlap in genetic etiology for tau levels and brain ventricular volume.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Establishing In-House Cutoffs of CSF Alzheimer's Disease Biomarkers for the AT(N) Stratification of the Alzheimer Center Barcelona Cohort

  • Orellana del Río, Adelina|||0000-0002-0204-1944
  • García-González, Pablo|||0000-0003-0125-5403
  • Valero, Sergi|||0000-0002-6599-948X
  • Montrreal Navarro, Laura|||0000-0002-0010-645X
  • De Rojas, Itziar|||0000-0002-2148-381X
  • Hernández, Isabel|||0000-0001-8119-393X
  • Rosende-Roca, Maitée|||0000-0003-1778-8175
  • Vargas, Liliana|||0000-0001-5685-5903
  • Tartari, Juan Pablo
  • Esteban de Antonio, Ester|||0000-0003-1965-6010
  • Bojaryn, Urszula
  • Narvaiza, Leire
  • Alarcón-Martín, Emilio|||0000-0002-0985-872X
  • Alegret, Montserrat|||0000-0002-8164-9500
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Lleó, Alberto|||0000-0002-2568-5478
  • Tárraga, Lluís|||0000-0002-8423-946X
  • Pytel, Vanesa
  • Cano, Amanda|||0000-0001-9567-4283
  • Marquié, Marta|||0000-0002-0660-0950
  • Boada, Mercè|||0000-0003-2617-3009
  • Ruiz Laza, Agustín|||0000-0003-2633-2495
Background: Clinical diagnosis of Alzheimer's disease (AD) increasingly incorporates CSF biomarkers. However, due to the intrinsic variability of the immunodetection techniques used to measure these biomarkers, establishing in-house cutoffs defining the positivity/negativity of CSF biomarkers is recommended. However, the cutoffs currently published are usually reported by using cross-sectional datasets, not providing evidence about its intrinsic prognostic value when applied to real-world memory clinic cases. Methods: We quantified CSF Aβ1-42, Aβ1-40, t-Tau, and p181Tau with standard INNOTEST® ELISA and Lumipulse G® chemiluminescence enzyme immunoassay (CLEIA) performed on the automated Lumipulse G600II. Determination of cutoffs included patients clinically diagnosed with probable Alzheimer's disease (AD, n = 37) and subjective cognitive decline subjects (SCD, n = 45), cognitively stable for 3 years and with no evidence of brain amyloidosis in 18F-Florbetaben-labeled positron emission tomography (FBB-PET). To compare both methods, a subset of samples for Aβ1-42 (n = 519), t-Tau (n = 399), p181Tau (n = 77), and Aβ1-40 (n = 44) was analyzed. Kappa agreement of single biomarkers and Aβ1-42/Aβ1-40 was evaluated in an independent group of mild cognitive impairment (MCI) and dementia patients (n = 68). Next, established cutoffs were applied to a large real-world cohort of MCI subjects with follow-up data available (n = 647). Results: Cutoff values of Aβ1-42 and t-Tau were higher for CLEIA than for ELISA and similar for p181Tau. Spearman coefficients ranged between 0.81 for Aβ1-40 and 0.96 for p181TAU. Passing-Bablok analysis showed a systematic and proportional difference for all biomarkers but only systematic for Aβ1-40. Bland-Altman analysis showed an average difference between methods in favor of CLEIA. Kappa agreement for single biomarkers was good but lower for the Aβ1-42/Aβ1-40 ratio. Using the calculated cutoffs, we were able to stratify MCI subjects into four AT(N) categories. Kaplan-Meier analyses of AT(N) categories demonstrated gradual and differential dementia conversion rates (p = 9.815). Multivariate Cox proportional hazard models corroborated these findings, demonstrating that the proposed AT(N) classifier has prognostic value. AT(N) categories are only modestly influenced by other known factors associated with disease progression. Conclusions: We established CLEIA and ELISA internal cutoffs to discriminate AD patients from amyloid-negative SCD individuals. The results obtained by both methods are not interchangeable but show good agreement. CLEIA is a good and faster alternative to manual ELISA for providing AT(N) classification of our patients. AT(N) categories have an impact on disease progression. AT(N) classifiers increase the certainty of the MCI prognosis, which can be instrumental in managing real-world MCI subjects.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Proteo-genomics of soluble TREM2 in cerebrospinal fluid provides novel insights and identifies novel modulators for Alzheimer's disease

  • Wang, Lihua
  • Nykänen, Niko-Petteri
  • Western, Daniel|||0000-0003-3725-9553
  • Gorijala, Priyanka
  • Timsina, Jigyasha
  • Li, Fuhai
  • Wang, Zhaohua
  • Ali, Muhammad|||0000-0002-1399-6631
  • Yang, Chengran
  • Liu, Menghan
  • Brock, William
  • Marquié, Marta|||0000-0002-0660-0950
  • Boada, Mercè|||0000-0003-2617-3009
  • Alvarez, Ignacio|||0000-0002-8537-3935
  • Aguilar, Miquel
  • Pastor, Pau|||0000-0002-7493-8777
  • Ruiz Laza, Agustín|||0000-0003-2633-2495
  • Puerta, Raquel|||0000-0002-1191-5893
  • Orellana del Río, Adelina|||0000-0002-0204-1944
  • Rutledge, Jarod
  • Oh, Hamilton
  • Greicius, Michael. D.
  • Le Guen, Yann Le
  • Perrin, Richard J.
  • Wyss-Coray, Tony
  • Jefferson, Angela
  • Hohman, Timothy J.
  • Graff-Radford, Neill
  • Mori, Hiroshi
  • Goate, Alison|||0000-0002-0576-2472
  • Levin, Johannes|||0000-0001-5092-4306
  • Sung, Yun Ju
  • Cruchaga, Carlos|||0000-0002-0276-2899
Triggering receptor expressed on myeloid cells 2 (TREM2) plays a critical role in microglial activation, survival, and apoptosis, as well as in Alzheimer's disease (AD) pathogenesis. We previously reported the MS4A locus as a key modulator for soluble TREM2 (sTREM2) in cerebrospinal fluid (CSF). To identify additional novel genetic modifiers of sTREM2, we performed the largest genome-wide association study (GWAS) and identified four loci for CSF sTREM2 in 3,350 individuals of European ancestry. Through multi-ethnic fine mapping, we identified two independent missense variants (p.M178V in MS4A4A and p.A112T in MS4A6A) that drive the association in MS4A locus and showed an epistatic effect for sTREM2 levels and AD risk. The novel TREM2 locus on chr 6 contains two rare missense variants (rs75932628 p.R47H, P=7.16×10; rs142232675 p.D87N, P=2.71×10) associated with sTREM2 and AD risk. The third novel locus in the TGFBR2 and RBMS3 gene region (rs73823326, P=3.86×10) included a regulatory variant with a microglia-specific chromatin loop for the promoter of TGFBR2. Using cell-based assays we demonstrate that overexpression and knock-down of TGFBR2, but not RBMS3, leads to significant changes of sTREM2. The last novel locus is located on the APOE region (rs11666329, P=2.52×10), but we demonstrated that this signal was independent of APOE genotype. This signal colocalized with cis-eQTL of NECTIN2 in the brain cortex and cis-pQTL of NECTIN2 in CSF. Overexpression of NECTIN2 led to an increase of sTREM2 supporting the genetic findings. To our knowledge, this is the largest study to date aimed at identifying genetic modifiers of CSF sTREM2. This study provided novel insights into the MS4A and TREM2 loci, two well-known AD risk genes, and identified TGFBR2 and NECTIN2 as additional modulators involved in TREM2 biology.